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Protein-protein  interactions are common  among 
transcriptional activators and may have important 
consequences for gene regulation. Using the mobility 
shift assay, we have identified a factor  that  enhances 
specific DNA binding of truncated  rat  androgen ( A R )  
and  glucocorticoid (GR) receptors  by 25- and 6-fold, 
respectively, through the formation of heteromeric 
complexes. This factor, designated  receptor  accessory 
factor, or  RAF, also potentiates DNA binding  of full- 
length human GR. RAF is temperature and trypsin 
sensitive and is present  in  a variety of  cultured mam- 
malian cells. By gel filtration RAF has a predicted 
molecular  mass  of 130 kDa. RAF enhancement  of AR- 
DNA binding is optimal with androgen  response ele- 
ment  DNA.  RAF  appears  to  interact directly with AR 
because 1) deoxycholate, which interferes with pro- 
tein-protein but not protein-DNA interactions, pre- 
vents RAF-AR-DNA  complex  formation, 2) RAF activ- 
ity is recovered  from  an  androgen  response  element 
DNA affinity column  only  in  the  presence  of  AR,  and 
3) RAF increases  the size of  an  AR*DNA  complex by 
gel filtration. Mutagenesis of truncated AR fragments 
indicates  that a region in the  NHz-terminal  domain is 
required for RAF to enhance AR-DNA binding. The 
interaction  of RAF with AR and GR suggests  that RAF 
might  influence  the ability of  these  nuclear  receptors 
to activate transcription. 
The androgen receptor (AR)’ is a member of a family of 
ligand-inducible intracellular regulators that activate or re- 
press  transcription of target genes (1, 2). These receptors are 
structurally and functionally organized into domains that 
mediate hormone binding, nuclear t ransl~at ion,  dimeriza- 
tion, DNA binding, and transcriptional  activation (3-5). The 
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The abbreviations used are: AR, androgen receptor; RAF, receptor 
accessory factor; GR, glucocorticoid receptor; PR, progesterone recep- 
tor;  HRE, hormone response element; ARE, androgen response ele- 
ment; MuARE, mutated androgen response element; ERE, estrogen 
response element; MMTV, mouse mammary tumor virus; C3, rat 
prostatein  C3 gene; PCR, polymerase chain reaction; DTT, dithio- 
threitol; bp, base pair(s);  PMSF, phenylmethylsulfonyl fluoride; PBS, 
phosphate-buffe~ saline; BSA, bovine serum albumin. 
AR, progesterone (PR), glucocorticoid (GR), and mineralo- 
corticoid receptors comprise a subclass of receptors based on 
sequence homology in  the DNA-binding domain and ability 
to bind  similar hormone response elements (HRE). For ex- 
ample, all of the receptors in  the AR subclass activate tran- 
scription  from the €€RE in the mouse mammary tumor virus 
long terminal  repeat (6-8). Therefore, the specificity of steroid 
hormone responses in this subclass may not be determined 
definitively by the minimal HRE sequence. 
Another subclass of intracellular receptors consists of the 
estrogen, thyroid hormone, retinoic acid, retinoid X, and 
vitamin D receptors, a grouping based on their ability to 
recognize the same HRE consensus sequence (9-12). Unlike 
the AR subclass, the orientation  and spacing of HRE half- 
sites  determine the specificity of DNA binding and  transcrip- 
tional  activation of each receptor (9,lO). Thyroid  and retinoic 
acid receptors can form heterodimers with retinoid X recep- 
tors, providing an additional level of complexity and specific- 
ity  in  transcriptional  control a t  thyroid hormone- and retinoic 
acid-responsive promoters (11-13). We hypothesized that het- 
erodimerization might occur among members of the AR-GR 
subclass of receptors. In  the course of our studies, we observed 
that rabbit reticulocyte lysate contains an activity that greatly 
enhances AR-specific DNA binding. In  this  report we describe 
a  protein that enhances specific DNA binding of AR and GR 
through the formation of heteromeric complexes. This pro- 
tein, designated receptor accessory factor, or RAF, is unique 
in comparison to other factors that enhance receptor binding 
to DNA and is present in extracts of cultured mammalian 
cells. 
EXPERIMENTAL PROCEDURES 
AR and GR Plasmid Constructs and Protein Expression- 
prAR(460-704) was constructed by digesting the rat AR bacterial 
expression vector PET-3b-trAR (14) at  the unique StuI restriction 
site  (at  rat AR amino acid 704) and adding BamHI linkers. Digestion 
with BamHI produced a 732-bp rAR DNA fragment (encoding amino 
acids 460-704) that was ligated into  the BamHI  site of the PET-3b 
bacterial expression vector (15). prGR(366-630) was constructed by 
digestion of the  rat GR eukaryotic expression vector p6RGR (kindly 
provided by Keith Yamamoto) with Sau3AI producing a 792-bp rGR 
DNA fragment (encoding amino acids 366-630) that was ligated into 
the BamHI site of PET-3b. prAR(521-704)  was constructed by am- 
plifying a region of rAR DNA corresponding to amino acids 521-704 
using the polymerase chain reaction (PCR)  and primers that included 
terminal  BamHI sites. This 549-bp rAR  DNA fragment was digested 
with BamHI and ligated into the BamHI site of PET-3a (15). 
prAR(460-626) was constructed by amplifying a region of rat AR 
DNA corresponding to amino acids 460-626 using PCR  and primers 
that included terminal  BamHI sites. This 498-bp  rAR  DNA fragment 
was digested with BamHI  and ligated into  the BamHI  site of PET- 
3a. phPR(484-727) was constructed by PCR amplification of the 
region of human PR DNA corresponding to amino acids 484-727 
using the  PR eukaryotic expression vector pSVL/PG5  as template 
(kindly provided by Geoffrey Greene) and primers that included 
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terminal  BamHI sites. This 729-bp human PR DNA fragment was 
digested with BamHI and ligated into  the  BamHI  site of PET-3a. 
The DNA sequences of plasmids constructed using PCR-amplified 
DNA fragments were confirmed by the dideoxy chain  termination 
method using deo~yadenosine[5'-a-~~SJthiotriphosphate (Amersham 
Corp.) and Sequenase (United States Biochemical). An ~ s c ~ r ~ c h ~  
coli expression plasmid encoding rat GR amino acids 407-556, desig- 
nated T7X556 (16), was kindly provided by Leonard Freedman. Each 
of these plasmids was expressed as a fusion protein that contains the 
first 10 amino acids of T7 gene 10, the sequence of which is encoded 
by the  PET-3 vectors (15). 
These bacterial expression plasmids were used to transform 
BLZl(DE3)pLysS cells, a strain of E. coli carrying the gene for T7 
RNA polymerase (provided by a DE3 lysogen) under the control of 
the  T7 promoter (15). Recombinant cells were grown at  37 "C to an 
optical density of 0.6-1.0 at 600 nm in 100 ml of Luria-Bertani 
medium containing 50 pg/ml ampicillin and 25  pg/ml chloramphen- 
icol. T7 RNA polymerase was induced by addition of isopropyl-1- 
thio-(3-D-galactopyranose to a final concentration of 0.5 mM. Three h 
after  induction, cells were collected by centri~gation  at 1,500 X g at  
4 'C, and partially purified bacterial  extracts were prepared as de- 
scribed (16). After freezing and thawing, the cell pellets were sus- 
pended in three volumes of lysis buffer (0.5 M NaC1, 1 mM EDTA, 
10% glycerol, 4 mM CaC12, 40 mM MgCl,, 5 mM dithiotbreitol (DTT), 
0.13  mg/ml  lysozyme,  20 pg/ml DNase I, 0.5 mM phenylmethylsul- 
fonyl fluoride (PMSF), 10 p M  leupeptin, 50 mM Tris, pH 7.5) and 
incubated for 10 min on ice. Deoxycholate was added to a final 
concentration of 0.05%, and  the suspension was stirred in an ice bath 
for 30 min, followed by centrifugation at  60,000 X g for 60 min a t  
4 'C. Polyethyleneimine was added to a  final  concentration of 0.2%. 
The solution was stirred for 10 min a t  4 "C,  followed by centrifugation 
at  15,000 X g for 30 min at  4 "C. Ammonium sulfate was added to the 
supernatant  to 35% saturation while stirring, and  after incubation 
for 15 min at 4 "C, the precipitate was collected by centrifugation at 
TGEDZB0 (50 mM NaCl, 0.5 mM EDTA, 10% glycerol, 5 mM DTT, 
10,000 X g for 10 min at 4 "C. The precipitate was suspended in 
50 p M  ZnC12, 0.5 mM PMSF, 10 p~ leupeptin, 50 mM Tris,  pH 7.5) 
and dialyzed against the same buffer. The expression of AR or GR 
peptides was confirmed by SDS-polyacrylamide gel electrophoresis 
and immunoblotting as described previously (17) using AR52 (18) 
and BuGR-2 antibodies (19). AR52 is  a polyclonal antibody directed 
against  a  synthetic peptide antigen  containing  amino acids 527-541 
of rAR (18). 
Preparation of  Whole  Cell Extracts-The following cells were  grown 
to 90% confluence in 150-mm2 tissue  culture flasks: human cervical 
carcinoma cells (HeLa), mouse Leydig tumor cells (MA10) (21), green 
monkey kidney cells (CVl),  and adenovirus-transformed human kid- 
ney 293 cells. Cells were washed with phosphate-buffered saline 
(PBS), collected by scraping in PBS,  and centrifuged for 10 min at  
1,500 X g. The cell pellets were resuspended in buffer A (0.45 M KCl, 
1 mM EDTA, 20%  glycerol, 2 mM DTT, 0.1 mM PMSF, 2 pM 
leupeptin, 1.5 pM pepstatin, 0.2 p M  aprotinin, 20 mM Tris,  pH 7.5) 
and sonicated three  times  on ice for 5 s. Cell extracts were incubated 
for 15 min at 4 "C and centrifuged at 13,000 X g for 15 min at 4 'C. 
The  supernatants were dialyzed in DNA binding buffer (50 mM KCl, 
1 mM EDTA, 1 mM DTT, 10% glycerol, 5 mg/ml bovine serum 
albumin (BSA), 10 mM Tris, pH 7.5), and protein concentrations 
were determined by the Bradford assay (Bio-Rad) using BSA as a 
standard. Rat erythrocyte lysate was prepared according to the 
method of  Adam and Gerace (22). 
Preparation of Baculooirus-expressed Full-length AR and GR-Full- 
length human AR and  rat AR were expressed in Spodoptera frugiperda 
(Sf9) cells infected with recombinant AR baculovirus using the con- 
ditions described? Sf9 cells (1 X lo7) were plated in 10-cm dishes in 
Grace medium with 10% fetal calf serum and infected with recombi- 
At 24- and 45-h post infection, 50 nM dihydrotestosterone was added 
nant  rat or human AR baculovirus a t  a multiplicity of infection of  4. 
to the medium. At 48-h post infection, cells were washed in PBS, 
harvested by scraping  in PBS,  and centrifuged at 12,000 X g for 15 S. 
The cell pellet was resuspended in hypertonic buffer (0.5 M NaCl, 1 
mM EDTA, 1 mM DTT, 10% glycerol, 0.5 mM PMSF, 0.1 p M  apro- 
tinin, 1 p M  leupeptin, 1 WM pepstatin, 1 mM benzamidine, 10 mM 
Tris, pH 7.4), and the cells were lysed by three cycles of freeze- 
thawing. The cell suspension was incubated on ice for 60 min with 
gentle vortexing every 15 min, followed  by centrifugation at  12,000 X 
a Wong, C.-I., Zhou, Z.-X., Sar, M., and Wilson, E. M. (1993) J.  
.____^- _I____ 
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g for 15 min at  4 "C. The  supernatant was dialyzed in DNA binding 
buffer on 0.025-pm pore filters and stored at  -80 "C. 
A frozen cell pellet from 50  ml of a suspension culture of Sf9 cells 
expressing full-length  human  GR was kindly provided by Ganesan 
Srinivasan and E. Brad Thompson. Sf9 cells were cultured in  suspen- 
sion as described (23). At a cell count of  2.0-2.5 X lo6 cellslml, cells 
were infected with recombinant GR baculovirus at a multiplicity of 
infection of 2-3. At 48-h post infection, the cells were lysed by two 
cycles of freeze-thawing in hypotonic buffer (0.1 mM EDTA, 1 mM 
DTT,  and  10 mM KPO,, pH 7.6). The cell lysate was centrifuged at  
100,000 X g for 30 min at  4 "C. Ammonium sulfate was added to  the 
supernatant  to 35% saturation with gentle stirring, and  the suspen- 
sion was incubated at  4 "C for 15 min followed by centrifugation at 
12,000 X g for 10 min at 4 "C. The precipitate was dissolved in 
hypotonic buffer and desalted using a Sephadex G-50 spin column. 
Some extracts of baculovirus-expressed AR  were prepared using the 
same procedure as  that for GR with and without protease inhibitors. 
DNA Binding and Mobility Shift Assay-The sense strands of the 
oligonucleotides used to prepare DNA probes for DNA binding assays 
included 1) C3-ARE, 5'-cgaccagAGTACGtgaTGTTCTcagg-3', de- 
rived from sequence within the  first  intron of the  rat prostatein  C3 
gene (14); 2) MuARE, 5'-tcgacAG~CGtgaTGATCT~-3', C3-ARE 
with two nucleotides mutated (doubleunderlinefin  the  HRE region; 
3) MMTV, 5'-cgaccaGTTACAaacTGTTCTcagg-3', derived from an 
HRE sequence within the mouse mammary tumor virus long terminal 
repeat (24); 4) ERE, 5'-tcgacAGGTCAgacTGACCTgtcga-3', derived 
from an ERE sequence in the 5' flanking region of the Xenopus 
vitellogenin A2 gene (25). Oligonucleotides were synthesized using 
the phosphamide method with an Applied Biosystems model 380B 
DNA synthesizer. Sense and antisense strands were annealed and 
purified by elution from  12% polyacrylamide gels. Double- stranded 
oligonucleotides were labeled with [ L Y - ~ ~ P ] ~ C T P  (Amersham Corp.) 
by the fill-in reaction using the Klenow fragment of DNA polymerase 
I (Bethesda Research Laboratories) to a specific activity of 5-10 X 
io5 counts/min/pmol. 
For DNA binding reactions, partially purified bacterial extracts 
containing rat AR or GR protein fragments (0.1-1.0 pg of total 
protein) were preincubated with 2 pg of polyfdl-dC) at  4 "C for 15 
min in DNA binding buffer in  a total reaction volume of 20 pl. 32P- 
Labeled oligonucleotide (0.02 pmol) was added, and  the mixture was 
incubated at  20 "C for 15 min, followed by an additional 15 min of 
incubation at  4 "C. The presence of  AR in the protein-DNA complexes 
was demonstrated by adding 0.1  mg/ml of the IgG fraction of  AR52 
and incubating for an additional 15 min at 20 "C (18). To analyze 
RAF effects on AR-DNA binding, partially purified rabbit reticulo- 
cyte lysate (5 pg) or whole cell extract (20 pg) was included in the 
preincubation step of the DNA binding reactions. DNA binding 
polyacrylamide gels (bisacryl, 37:l) in 0.5 X TBE (45 mM Tris-borate, 
reactions were analyzed by electrophoresis on 5% nondenaturing 
pH 8.0, and 1 mM EDTA) at  10 V/cm at  4 "C. Gels were dried and 
protein-DNA complexes visualized by autoradiography on Kodak X- 
Omat AR film. The degree of RAF enhancement of DNA binding was 
quantitated by densitometry of the autoradiographs. 
Partial Purification and Chromatographic Analysis of RAF and A R .  
DNA Complexes-Untreated rabbit reticulocyte lysate (Promega) was 
partially purified by anion-exchange chromatography using a 1-ml 
Mono Q column (Pharmacia  LKB Biotechnolo~ Inc.). Ten mg of 
lysate protein  in 100 pl was chromatographed in 0.1 M KC1 and 20 
mM Tris, pH 8.0, at 4 "C and eluted with a gradient of  0.1-1.0 M KC1 
pore cellulose filters (Millipore) in DNA binding buffer. RAF activity 
at a flow rate of 1.0 ml/min. Fractions were dialyzed on 0.025-pm 
was assayed in the presence of rAR(460-704) using the mobility shift 
assay. RAF activity eluted at 0.25-0.30 M KCl. 
To determine the Stokes  radius of RAF, 25  mg  of lysate in 500 pl 
was chromatographed on a Sephadex G-150 (Pharmacia) column (1.5 
X 25 em) equilibrated with DNA binding buffer (without BSA) at  a 
flow rate of 2  ml/h at 4 "C. Fractions were analyzed for RAF activity 
by the mobility shift assay. The column was calibrated with molecular 
weight standards with known Stokes  radii (bovine 7-globulin, 53.0 A; 
BSA,  35.5 A; chicken ovalbumin, 27.3 A; and horse myoglobin, 20.7 
A) (20). The Stokes radius of RAF was determined by calculating the 
(-log Kav)lfi of RAF (where K., is the distribution coefficient) and 
plotting this value on  a  linear regression curve of the (-log Kav)''' 
and Stokes  radii of the protein standards (20). 
To investigate possible DNA binding activity of RAF, an ARE 
affinity column was prepared according to  the method of Kadonaga 
and  Tjian (26) by coupling concatemers of the C3-ARE oligonucleo- 
tide to cyanogen bromide-activated Sepharose 4B (Sigma). C3-ARE 
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affinity resin (1 ml) was equilibrated with DNA binding buffer in  a 
Bio-Rad Econo-Column at  4 "C. Rabbit reticulocyte lysate (30  mg) 
alone or combined with rAR(460-704) extract (100 pg) was incubated 
with DNA binding buffer and poly(d1-dC) (50 pg) in a total volume 
of 170 pl for 15 min at 4 "C. The protein-DNA mixture was applied 
to  the affinity resin by gravity flow at  a rate of 4 ml/h. The column 
was washed with 8 ml of DNA binding buffer, and bound proteins 
were eluted with 1.0 M KCI. Fractions were dialyzed on 0.025-pm 
pore filters  in DNA binding buffer, and RAF activity was analyzed 
by the mobility shift assay in the presence of rAR(460-704). 
To determine the Stokes radii of AR-DNA  and  RAF-AR-DNA 
complexes, partially purified samples of  AR and combined RAF/AR 
were prepared by ARE affinity chromatography. rAR(460-626) ex- 
tract (15 pg) either alone or combined with 750  pg  of partially purified 
lysate were incubated with 100 pg  of poly(d1-dC) for 15 min at  4 "C 
in DNA binding buffer in a total volume of 100 pl. Each  mixture was 
chromatographed on the ARE affinity column, eluted with 1.0 M KCI, 
and dialyzed as described above. The two sets of ARE affinity column 
fractions were used to prepare DNA binding reactions. Each set of 
pooled fractions was incubated with 2 pg of poly(d1-dC) for 15 min 
at  4 "C in DNA binding buffer in  a total volume of 50 pl. Unlabeled 
C3 oligonucleotide (35 ng) was added to each reaction, and the 
incubation was continued for an additional 30 min at  4 "C. The 
binding reactions were chromatographed on a Superose 12 (Phar- 
macia) column (1 X 30 cm) equilibrated in DNA binding buffer 
(without BSA) at  a flow rate of  0.5 ml/min at  4 "C. Fractions (0.35 
ml) were collected and analyzed for AR-DNA binding activity by the 
mobility shift assay in  the presence of AR52 antibody to enhance 
sensitivity of detecting AR-DNA binding. AR-DNA binding was 
quantitated by densitometry. The Superose 12 column was calibrated 
using the same protein standards described above for the SephadFx 
G-150 column, as well as bovine thyroglobulin (Stokes radius 85 A). 
Stokes radii of the AR.DNA and RAF .AR.DNA complexes were 
calculated as described above. 
RESULTS 
Enhancement of Specific  AR-DNA Binding by Antibody and 
R4F-In order to study the effect of protein-protein interac- 
tions  on AR-DNA binding, we used an E. coli-expressed rat 
AR fragment, rAR(460-704), which includes the DNA binding 
domain, the hinge region, and 82 and 45 amino acids of the 
NH2-terminal and COOH-terminal  domains, respectively 
(Fig. 1). rAR(460-704) was expressed as a fusion protein with 
N-TERMINAL DNA HINGE STEROID 
FUN Length i S47. 607 659 902 
rAR 
Epnop. for AR ~b 
m"541 
460 
rAR (460.704) np-E l7 gem 10 
FIG. 1. Bacterial expression of rat AR(460-704). A DNA 
fragment encoding amino acids 460-704  of rat AR was ligated into 
the BamHI site of the PET-3b bacterial expression vector. The 
resulting plasmid, prAR(460-704). encodes a fusion protein which 
includes the rAR(460-704) fragment in-frame with the first  10  amino 
acids of T7 gene 10.  rAR(460-704) is expressed in the E. coli strain 
BLBl(DE3)pLysS under control of the  T7 promoter. rAR(460-704) 
includes the DNA-binding domain, hinge region, and portions of the 
NHZ-terminal and steroid-binding domains. This AR fragment also 
includes a region (amino acids 521-541) recognized by a peptide- 
generated AR antibody, AR52. 
1oox 1oox 
ARE  Ab  Ab  Ab 
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FIG. 2. Enhancement of specific AR-DNA  binding  by  anti- 
body and RAF. The binding of rAR(460-704) to the C3-ARE 
oligonucleotide was analyzed using the mobility shift assay in  a 5% 
nondenaturing polyacrylamide gel. Each binding reaction contained 
32P-labeled C3-ARE (0.02 pmol) and 2 pg of poly(d1-dC). Lunes 1-3 
and 5-7 contained 0.1 pg of rAR(460-704) bacterial extract (AR) ;  
lanes 4-7 and 10-12 contained 5 pg of rabbit reticulocyte lysate 
(lysate) protein  partially purified by chromatography on a Mono Q 
column; lanes 8,9, and 12 contained 0.1  pg  of control bacterial extract 
( B E ) ;  lanes 2 and 6 contained 2.0 pmol of unlabeled C3-ARE; lanes 
3, 7,9,  and 11 contained 0.1 pg  of  AR52 antibody (Ab). Protein-DNA 
complexes are designated: A, AR.DNA complex; B, RAF.AR.DNA 
complex; and C, Ab.AR.DNA complex. Unbound, 32P-labeled C3- 
ARE probe migrated to  the bottom of the gel. 
the  first 10 amino acids of T7 gene 10 under  control of the 
T7 promoter. The AR antibody (AR52) used in this study 
recognizes an epitope just NH2-terminal to the DNA-binding 
domain (Fig. 1). 
Using the gel mobility shift assay, we analyzed the ability 
of rAR(460-704) to bind  a 28-bp DNA fragment that contains 
an ARE derived from the first intron of the  rat prostatein C3 
gene (C3) (14). This rAR fragment bound to the C3-ARE 
(Fig. 2, lane 1, complex A ) ,  and  its mobility was representative 
of an AR homodimer under  these  experimental conditions? 
AR-DNA binding was competed effectively by the addition of 
excess unlabeled C3-ARE (lane 2). When AR52 antibody was 
added to  the reaction, an approximately 30-fold enhancement 
of DNA binding occurred coincident with a shifted band, 
suggesting stabilization of AR-DNA binding by association 
with the antibody (Fig. 2, lane 3, complex C). This stabilization 
phenomenon has been reported previously for PR in mobility 
shift assays using PR antibodies (27). 
In  initial experiments to identify possible factors that as- 
sociate with AR and influence DNA binding, we tested  rabbit 
reticulocyte lysate. The addition of lysate caused a 25-fold 
enhancement of DNA binding associated with a novel shifted 
complex (Fig. 2, lane 5, complex B ) ,  which was competed by 
excess unlabeled C3-ARE probe (lane 6). Addition of antibody 
caused a shift essentially identical to  that observed with AR 
and antibody  alone (Fig. 2, compare lanes 7 and 3, complex 
C). This indicated that,  at these  concentrations of antibody 
and lysate, AR antibody  interfered with formation of the AR- 
lysate complex. Similar  results were obtained using an E. coli- 
expressed human AR fragment encompassing amino acids 
477-721 (data  not shown). 
K. B. Manchke, unpublished observations. 
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Neither the control E. coli extract nor the reticulocyte lysate 
alone  contained DNA binding  activity (Fig. 2, lanes 8 and 10). 
Addition of AR antibody did not augment DNA binding of 
these  fractions  indicating that  they lack AR protein (lanes 9 
and 11 ). Furthermore,  no C3-ARE binding was observed when 
lysate was added to a control bacterial extract (lane 12). 
Therefore, rabbit reticulocyte lysate contains an activity, 
RAF, that enhances AR binding to a known androgen re- 
sponse element. 
Effects of Temperature, Trypsin, and Deoxycholate on RAF 
Activity-The temperature  and  trypsin sensitivity of the ly- 
sate-AR-DNA complex was investigated. Enhancement of 
AR-DNA binding by lysate was equivalent  whether the DNA 
binding reaction was performed a t  20 or 4 "C (Fig. 3A, lanes 
2 and 3, complex B). When  lysate was pretreated at  60 "C for 
10 min, RAF activity was abolished (lane 4 ) .  Likewise, pre- 
treatment of lysate with trypsin, followed  by trypsin inhibitor, 
eliminated RAF activity (lane 5 ) .  Addition of antibody to  the 
same reaction resulted in the typical AR-antibody complex 
indicating that trypsin had been inhibited completely and 
that AR remained intact (lane 6, complex C). These results 
indicate that RAF is a  protein. 
To investigate a  direct  interaction between RAF and AR, 
we used the mild anionic detergent deoxycholate, which is 
known to disrupt protein-protein interactions (28). In the 
absence of lysate, 0.7% deoxycholate caused limited disrup- 
tion of AR-DNA binding  in the mobility shift assay (Fig. 3B, 
AR + ' + " + " + ' +  + 
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B AR + 
AR Lysate 
DOC TT 
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FIG. 3. Sensitivity of RAF activity  to temperature, trypsin, 
and deoxycholate. Mobility shift assays were performed using the 
conditions described in the legend to Fig. 2, except as noted. DNA 
binding reactions contained 32P-labeled C3-ARE (0.02) pmol, and  as 
indicated, 0.1  pg rAR(460-704) extract ( A R ) ,  5 pg  of partially purified 
rabbit reticulocyte lysate (lysate), and 0.1  pg  of  AR52 antibody (Ab) .  
Protein-DNA complexes are designated A ,  AR.DNA complex; €3, 
RAF . AR . DNA  complex; and C, Ab. AR . DNA complex. A ,  tempera- 
ture and trypsin sensitivity. In lanes 2 and 3, the DNA binding 
reactions were performed at  20 and 4 "C, respectively. In lane 4, the 
lysate was pretreated at  60 "C for 10 min, and the DNA binding 
reaction was performed at  20 "C. In lanes 5 and 6, lysate was pre- 
treated with 5 ng/ml trypsin,  type I, from bovine pancreas  (Sigma) 
for 15 min at 20 "C followed by treatment with 500 ng/ml trypsin 
inhibitor,  type I-S, from soybean (Sigma) for an additional 15 min at  
20 "C; trypsin-treated lysate was added to  the preincubation step of 
the DNA binding reaction. €3, effect of deoxycholate. Each DNA 
binding reaction was performed in the presence of  0.6% Nonidet P- 
40. In addition, lanes 2 and 4 contained 0.7% deoxycholate (DOC). 
lanes I and 2, complex A). However, the enhanced, shifted 
complex observed with AR and lysate (lane 3, complex B )  was 
eliminated by deoxycholate (lane 4 ) .  Under these  conditions 
AR-DNA binding remained essentially intact (Fig. 3B, lane 
4, complex A) .  The ability of deoxycholate to disrupt the 
lysate complex suggests that RAF enhancement of AR-DNA 
binding  results from direct  protein-protein  interactions. 
DNA Specificity of RAF-AR Interaction-The DNA se- 
quence specificity of AR. DNA complex formation was tested 
using  a  variety of labeled DNA probes containing different 
hormone response elements. C3-ARE was mutated at  two 
nucleotide positions (double underline)  in the  HRE region to 
produce MuARE (5'-tcgacAGTTCGtnaTGATCTg-3'). These 
2 residues were shown previously to be important for AR- 
DNA binding and transcriptional activation." AR-DNA bind- 
ing was undetectable with the MuARE probe (Fig. 4, lane 4 ) ,  
and RAF enhancement of AR-DNA binding was markedly 
diminished in comparison with the C3-ARE probe (lanes 3 
and 5 ) .  Androgen response element DNA from the mouse 
mammary tumor virus long terminal repeat (MMTV, 5'- 
cgaccaGTTACAaacTGTTCTcagg-3') bound weakly to AR 
alone (Fig. 4, lane 6), while addition of lysate enhanced AR- 
DNA binding by 25-fold (lane 8). AR-DNA binding was not 
detected with an estrogen response element (ERE, 5'- 
tcgacAGGTCAgacTGACCTgtcga-3') (Fig. 4, lane 9), al- 
though weak  DNA binding was observed upon lysate addition 
(lane 11 ). Thus, specific AR-DNA binding is a  prerequisite 
for optimal RAF stabilization of AR. DNA complexes. 
Cell Type Specificity of RAF-The cell type specificity of 
RAF was analyzed using  a variety of cell lysates prepared in 
high salt buffer. RAF-like activity was detected in several cell 
types  tested (Fig. 5). HeLa cells (lane 10) and mouse  Leydig 
tumor MA10 cells (lane 12) had the highest relative RAF 
activity. Rabbit reticulocyte lysate (lane 3 )  and  rat erythro- 
cyte lysate (lane 6) had moderate RAF activity, based on total 
ARE  Mu E MMTV ERE 
AR ' +  - + ' I +  + ' I +  - + ' I +  - + '  
Lysate - + + - + - + + -  + +  
""" 
1 2  3 4 5 6 7 8 9 1 0 1 1  
FIG. 4. DNA specificity of RAF-AR interaction. AR-DNA 
binding was tested using 32P-labeled HRE-containing oligonucleo- 
tides in the mobility shift assay under the conditions described in the 
legend of Fig. 2. Lunes 1-3 contained an ARE  from the first intron 
of the  rat prostatein C3 gene ( A R E )  (14); lanes 4 and 5 contained the 
C3-ARE with two nucleotide positions mutated in the HRE region 
(MuARE); lanes 6-8 contained an HRE from the MMTV  long 
terminal  repeat ( M M T V )  (24); lanes 9-11 contained an  ERE from 
the Xenopus vitellogenin A2 gene ( E R E )  (25). 
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FIG. 5. Cell type specificity  of RAF. Whole cell lysates were 
prepared in a high salt (0.45 M KC1) buffer (see "Experimental 
Procedures"): human cervical carcinoma cells ( H e h ) ,  mouse Leydig 
tumor cells (MAIO), monkey kidney cells (CVl) ,  and adenovirus- 
transformed  human kidney cells (293).  Rat erythrocyte lysate (REL)  
was prepared using a hypotonic buffer (22). Rabbit reticulocyte lysate 
(lysate) was obtained from Promega. Whole cell extracts (20 pg) were 
analyzed by the mobility shift assay in the presence of 0.1 pg of 
rAR(460-704) extract by addition to  the preincubation step of the 
DNA binding reactions. Lanes 3 and 4 contained 20 and 200 pg, 
respectively, of crude rabbit reticulocyte lysate. 
protein concentration. RAF activity was  very weak or unde- 
tectable in monkey kidney CV1 cells (lane 8) and adenovirus- 
transformed human kidney 293 cells (lane 1 4 )  under these 
experimental conditions. Thus, RAF is  present  in different 
cell types at varying concentrations. 
The AR NH2-terminal Region Is Required for RAF Inter- 
action-We performed mutagenesis of the rAR(460-704) frag- 
ment to determine the amino acid regions required for RAF- 
AR complex formation. Deletion of amino acids 460-520 just 
NH2-terminal of the AR-DNA-binding domain produced the 
fragment rAR(521-704),  which bound DNA in the mobility 
shift assay (Fig. 6, lane 3). However, the addition of lysate 
failed to promote complex formation (lane 4 )  like that ob- 
served for rAR(460-704) ( l a n e  2). Deletion of amino acids 
627-704 just COOH-terminal of the DNA-binding domain 
produced the fragment rAR(460-626),  which bound DNA and 
formed an RAF. AR complex upon lysate addition (Fig. 6, 
lanes 5 and 6). Therefore, a region encompassing amino acids 
460-520 in the NHp-terminal domain of AR is required for 
interaction with RAF. 
Both rAR(521-704) and rAR(460-626) contain the epitope 
for the antibody AR52. In  the mobility shift assay addition of 
antibody to DNA binding reactions containing each of these 
AR fragments produced a  band of slower mobility associated 
with enhancement of DNA binding (data  not shown). 
Chromatographic Analysis of RAF and AR. DNA Com- 
plexes-The molecular mass of RAF was estimated by gel 
filtration on Sephadex G-150. Fractions were analyzed in the 
mobility shift assay in the presence of rAR(460-704).  RAF 
activity eluted at a Stokes radius of 47 A (Fig. 7), which 
correlates with a predicted molecular mass of 130 kDa for 
globular proteins. 
The DNA binding activity of RAF alone was investigated 
by chromatographing lysate on a DNA affinity column con- 
taining concatemers of the C3-ARE. Bound protein was eluted 
rAR I "
' rAR(460-704)  
rAR(521-704)  
r A R ( 4 6 0 - 6 2 6 )  [-I 
902 
rAR(460-704) rAR(S21-704) rAR(460-626) 
A R ' +  + " +  + ' I +  + '  
Lysate - + - + - + 
1 2  3 4 5 6  
FIG. 6. AR NH2-terminal  region  required  for RAF interac- 
tion. 61 NHZ-terminal amino acids and 78 COOH-terminal amino 
acids were deleted from rAR(460-704) to produce rAR(521-704) and 
rAR(460-626), respectively, as described under "Experimental Pro- 
cedures." rAR is a schematic representation of the full-length rat AR. 
The mobility shift assay was performed using the 32P-labeled C3- 
ARE probe under the same conditions described in the legend of  Fig. 
2. Lanes 1 and 2 contained 0.1 pg of rAR(460-704) extract; lanes 3 
and 4 contained 0.2 pg of rAR(521-704) extract; lanes 5 and 6 
contained 0.01  pg  of rAR(460-626) extract; lanes 2 ,4 ,  and 6 contained 
5 pg of partially purified rabbit reticulocyte lysate. 
with 1.0 M KC1, and fractions were  dialyzed and analyzed by 
the mobility shift assay in the presence of rAR(460-704). As 
shown by fractions 3-8 in Fig. 8 (left panel), RAF was not 
retained by the ARE affinity column in the absence of AR. 
However, addition of rAR(460-704) to lysate prior to chro- 
matography caused RAF to bind to  the ARE affinity column, 
as indicated by the appearance of the RAF . AR. DNA complex 
(Fig. 8, fractions 4-7, right panel). The control lane (C) 
contained both rAR(460-704) and lysate. These results sug- 
gest that RAF associates with DNA  only in the presence of 
AR and raise the possibility that AR and RAF interact di- 
rectly. An alternative explanation is that  an inhibitor of AR- 
DNA binding has been purified away  from the lysate by the 
ARE-DNA affinity column resulting in enhanced AR-DNA 
binding. 
To obtain additional evidence for direct protein-protein 
interaction between  RAF and AR, AR. DNA and RAF AR 
DNA  complexes  were analyzed by gel filtration. Samples of 
rAR(460-626) alone or in combination with partially purified 
lysate were chromatographed, eluted, and dialyzed by ARE 
affinity chromatography as described above and under "Ex- 
perimental Procedures.'' Each set of ARE affinity column 
fractions was incubated with excess unlabeled C3  oligonucle- 
otide and chromatographed on  a Superose 12 (Pharmacia) gel 
filtration column. Gel filtration fractions were analyzed by 
the mobility shift assay in the presence of AR52 antibody 
(Fig. 9). The peak of AR-DNA binding activity with AR alone 
eluted at  a Stokes radius of 47 A. In contrast, AR-DNA 
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FIG. 7. Gel filtration of RAF. Lysate and protein standards 
were chromatographed on  a Sephadex C-150 column, and fractions 
were analyzed by the mobility shift  assay  in the presence of  1.0  pg  of 
rAR(460-704) extract,  as shown in the lower panel. The control  lane 
( C )  contained lysate and rAR(460-704). The upper panel displays the 
linear regression analysis of the (-log Kdl’* and Stokes radii of 
protein standards. The Stokes radius of RAF was determined by 
plotting the calculated (-log KaV)”* on the  standard curve. 
binding activity with the combined AR/lysate sample eluted 
at  a Stokes radius of 66 A, suggesting the association of an 
additional protein(s) with the AR.DNA complex. When col- 
umn fractions from the combined AR/lysate sample were 
analyzed without AR antibody, RAF activity also eluted at  a 
Stokes radius of  66 A (data  not shown). These results indicate 
that RAF interacts directly with AR as a component of the 
DNA-protein complex. 
Enhancement of Glucocorticoid Receptor DNA Binding by 
RAF-The specificity of RAF activity for AR was tested using 
a corresponding fragment of the  rat glucocorticoid receptor, 
rGR(366-630). This GR fragment alone bound efficiently to 
the C3-ARE  sequence  (Fig. lOA, lane 1 ). Mobility of the  GR. 
DNA  complex in lane 1 is representative of a GR homodimer 
under these experimental conditions? When lysate was added, 
DNA binding was enhanced 6-fold. and a shifted complex 
with mobility identical to  that of the RAF. AR. DNA  complex 
was observed (Fig. lOA, lane 3) .  The addition of BuGR-2 
antibody to GR alone produced a shifted band consistent with 
an antibody-GR-DNA complex (lane 4) .  The  GR. RAF  DNA 
complex (lane 3 )  was disrupted by the BuGR-2 antibody, 
resulting in the appearance of the typical antibody-GR-DNA 
band (data  not shown). DNA binding of T7X556 (16), a rat 
GR fragment encompassing amino acids 407-556, was not 
Applied to 
DNA Column: Lysate  Lysate + AR 
1 
3 4 5 6 7 8   3 4 5 6 7 8  C 
FRACTION # 
(DNA binding assayed in presence of AR) 
FIG. 8. DNA affinity chromatography of RAF. Rabbit retic- 
ulocyte lysate alone (left panel) or a combination of lysate and 
rAR(460-704) (right panel) was chromatographed on  a DNA affinity 
column containing concatemers of C3-ARE DNA. Bound protein was 
eluted with 1.0 M KCl, and fractions were  dialyzed in DNA binding 
buffer. The presence of RAF activity in each fraction was determined 
using the mobility shift assay in the presence of  1.0 pg of rAR(460- 
704) extract with the same conditions described in the legend of  Fig. 
2. Lanes 3-8 correspond to fractions 3-8 collected after elution with 
1.0 M KCI. The control lane ( C )  contained lysate and rAR(460-704). 
10,m 
T G A  0 
Fraction Number 
FIG. 9. Gel filtration of AR-DNA and RAF-AR-DNA com- 
plexes. rAR(460-626) alone or in combination with partially purified 
lysate was chromatographed on the ARE affinity column, eluted, and 
dialyzed, as described in the legend of  Fig. 8 and  under “Experimental 
Procedures.” Each  set of ARE affinity-purified fractions was incu- 
bated with 35 pg of C3 oligonucleotide and chromatographed on  a 
Superose 12 column (Pharmacia). Gel filtration  fractions were ana- 
lyzed by the mobility shift assay, as described in legend of Fig.  2, in 
the presence of AR52 antibody, and AR-DNA binding was quanti- 
tated by densitometry. The Stokes radii of the AR.DNA (A) and 
RAF.AR.DNA (0) complexes were determined by the method de- 
scribed in the legend to Fig. 7 and under “Experimental Procedures.” 
The Superose 12 column was calibrated with protein standards of 
known Stpkes radii: bovine thyroglobulin (T), 85 A; bovine y-globulin 
( G ) ,  53.0 9; bovine serum albumin ( A ) ,  35.5  A; and chicken ovalbumin 
( O ) ,  27.3 A. 
enhanced or shifted by lysate, suggesting that amino acid 
regions 366-406 and/or 557-630 are required for RAF inter- 
action with GR. 
The ability of RAF to interact with the full-length GR and 
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FIG. 10. Enhancement of glucocorticoid receptor DNA 
binding by RAF. A ,  effect of RAF on truncated rGR. Upper  panel, 
rGR shows schematically the full-length rat glucocorticoid receptor. 
rGR(366-630) contains the DNA-binding domain, hinge region, and 
portions of the NH,-terminal and COOH-terminal domains and was 
expressed in E. coli as described under  “Experimental Procedures.” 
Lower panel, the mobility shift assay was performed under the same 
conditions described in the legend of  Fig. 2 using 32P-labeled C3-ARE 
oligonucleotide. Lanes 1,3, and 4 contained 1.0  pg  of rGR(366-630); 
lanes 2 and 3 contained 5 pg  of partially purified rabbit reticulocyte 
lysate; lane 4 contained a 1: lO dilution of BuGR-2 antibody. B, effect 
of RAF on the full-length human GR. The mobility shift  assay was 
performed using 32P-labeled C3-ARE under the same conditions 
described in the legend of  Fig. 2, except that DNA binding reactions 
were electrophoresed on a 4% nondenaturing polyacrylamide gel. 
Lanes 1 and 3 contained 1.0  pg  of human GR (hGR) extract prepared 
from recombinant baculovirus-infected Sf9 cells; lanes 2, 3, and 5 
contained 5 pg  of partially purified rabbit reticulocyte lysate; lanes 4 
and 5 contained 1.0  pg  of control Sf9 extract (Sf9). Preparations of 
rabbit reticulocyte lysate chromatographed on the Mono Q column 
occassionally exhibited nonspecific DNA binding (lane 2) .  Protein- 
DNA complexes are designated: A, hGR-DNA complex; B, RAF. 
hGR. DNA  complex; and m, nonspecific complexes. 
AR  was also investigated. Human GR, expressed in S. frugi- 
perdu (Sf9) cells using a  recombinant baculovirus expression 
vector (23), bound the C3-ARE sequence (Fig. 1023, lane 1, 
complex A ) .  Addition of lysate  shifted the  human  GR  band  to 
a more slowly migrating complex and enhanced DNA binding 
3-fold (lam 3, complex B). Similar  experiments  with baculo- 
virus-expressed full-length rat  and  human AR did not reveal 
a  shifted  band.  Neither the control Sf9 extract  nor  the com- 
bination of lysate and Sf9 extract reproduced these specific 
complexes (lanes 4 and 5 ) .  Thus, RAF interacts with and 
enhances DNA binding of a rat  GR fragment and  the full- 
length  human GR, but RAF activity is not evident  with full- 
length AR. 
A truncated fragment of the  human progesterone receptor, 
hPR(484-727), which is comparable to rAR(460-704) and 
rGR(366-630), was tested  for its ability to interact with RAF. 
Although this  PR fragment  bound the C3-ARE, addition of 
lysate did not enhance  PR-DNA binding. When  the MMTV 
oligonucleotide was used, however, lysate shifted the PR. 
DNA complex to a slower mobility, yet PR-DNA  binding was 
not enhanced (data  not shown). 
DISCUSSION 
We have identified an  apparently ubiquitous  factor, RAF, 
that enhances specific DNA binding of truncated fragments 
of rat AR and GR, as well as full-length human GR. RAF 
interacts directly with AR based on several observations: 1) 
RAF causes a shift in migration of the AR.DNA complex in 
the mobility shift assay and by  gel filtration,  2) AR antibody 
interferes with formation of the RAF.AR. DNA complex, 3) 
the protein-protein dissociating agent deoxycholate disrupts 
the RAF. AR. DNA complex, and 4) RAF activity is recovered 
from an ARE-DNA affinity column only in the presence of 
AR. 
Although RAF is  the first example of an accessory factor 
that affects AR-DNA binding, factors that enhance DNA 
binding of other nuclear receptors have been identified. 
Within  the AR-GR-PR subclass of receptors, a  heat-stable, 
0.7-3-kDa factor identified in rat  HTC cells was shown to 
enhance DNA binding of GR 4-fold (29). DNA binding of 
PR-B is enhanced 4-fold by an activity in nuclear extracts of 
T47D human  breast cancer cells (30). This  PR factor does 
not  interact stably with PR since the mobility of the  PR. 
DNA complex was not  altered in the mobility shift assay (31). 
Enhancement of DNA binding by the formation of hetero- 
meric complexes is common among the thyroid hormone- 
retinoic  acid-vitamin  D subclass of nuclear receptors. Thyroid 
hormone receptor auxiliary proteins  enhance DNA binding of 
thyroid  hormone  receptors a1 and @1 by binding to a  thyroid 
hormone response element and associating with the thyroid 
hormone receptor (32-35). Similar  factors have been identi- 
fied for efficient binding of vitamin  D receptor (36, 37) to its 
response element. Enhancement of retinoic acid receptor- 
DNA binding is mediated by heterodimerization with a novel 
intracellular receptor, the retinoid X receptor @ (11, 12, 38). 
Retinoid X receptor B forms heterodimers not only with 
retinoic acid receptors, but also with thyroid hormone and 
vitamin  D receptors, resulting  in  enhanced DNA binding (11, 
12)  and  transcriptional activation (11). Retinoid X receptor @ 
does not enhance DNA binding of GR (11). DNA binding of 
the chicken ovalbumin upstream  promoter receptor, a member 
of the  orphan receptor subclass, is stabilized by the general 
transcription factor TFIIB (S300II) (39,40). 
We have considered other known receptor-binding proteins 
that might account for RAF activity. Smith et al. (41)  reported 
that  rabbit reticulocyte lysate promotes association of chicken 
PR with the heat shock proteins, hsp90 and hsp70, and 
Scherrer et al. (42)  demonstrated  a  similar finding with GR. 
However, neither hsp7O (44)  nor hsp90 (42) associates with 
the DNA-bound form of PR or GR, respectively. Furthermore, 
antibodies that recognize hsp7O and hsp90, or  an antibody 
that recognizes a 59-kDa protein that associates with non- 
transformed AR, ER,  PR,  and GR (45), did not  disrupt  or 
shift RAF.  AR. DNA complexes.4 We considered several gen- 
eral transcription factors as possible candidates for RAF. 
When RAF was chromatographed on phosphocellulose, its 
elution pattern was similar to  that reported for TFIIA (46). 
However, purified HeLa cell fractions TFIIA  or  TFIID (kindly 
provided by Danny Reinberg) or bacterially expressed recom- 
binant human TATA-binding protein (Promega), did not 
have RAF activity  in the mobility shift assay.4 Several reports 
have indicated that  GR  is capable of interacting directly with 
the  AP-1  transcription factor, either  to activate or repress GR 
transcriptional activity depending on the cellular and pro- 
moter context (46-49). When c-jun was tested for RAF activ- 
ity, however, the DNA binding activity of rAR(460-626) was 
unaffected.4 Yoshinaga et al. (50)  reported recently that  the 
yeast transcriptional activators SWI1, SWI2, and SWI3  are 
required for rat GR to enhance transcription in yeast. Al- 
though we have not examined yeast extract for RAF activity, 
T7X556, a rat GR peptide encompassing amino acids 407- 
‘ S. R. Kupfer, unpublished observations. 
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556, did not  interact with RAF but did coimmunoprecipitate 
with SW13 (50). 
The estimated molecular mass of RAF,  130 kDa, is larger 
than any other factors known to enhance receptor DNA 
binding. We have not ruled out  the possibility, however, that 
RAF is an oligomeric  complex.  As many as three RAF . AR. 
DNA complexes  were observed upon addition of lysate to AR, 
possibly reflecting the presence of incomplete forms of an 
oligomeric  complex. The paradigm of multiprotein complexes 
is evident from the association of heat shock proteins with 
inactivated  steroid receptors (41, 42), and  the same concept 
may apply to activated receptor forms. Yoshinaga et al. (50) 
observed that the coimmunoprecipitation of rat GR with 
SWI3 required SWIl  and SWI2, suggesting the possibility of 
a  muitiprotein complex. 
The requirement of the AR NHz-terminal domain for RAF 
stabilization of AR-DNA binding indicates a novel protein- 
protein  interaction  site for the nuclear receptor family. En- 
hancement of DNA binding by retinoid X receptor and  thy- 
roid hormone receptor auxiliary protein requires a region 
within the COOH-terminal ligand-binding domains of reti- 
noic acid (11, 12) and thyroid hormone receptors (34, 35), 
respectively. A series of heptad  repeats of hydrophobic resi- 
dues in  the COOH-terminal regions of these receptors was 
implicated as a dimerization interface (51, 52). A comparison 
of amino acid sequence between the RAF interaction  site in 
rat AR (amino acids 460-520) and  the comparable region of 
rat GR (amino acids 357-419) revealed only 17% homology 
between these regions without clusters of high sequence iden- 
tity. As suggested for the putative  COOH-terminal dimeriza- 
tion region, the spacing of conserved residues in the NH2- 
terminal regions of AR and GR might be more critical for 
RAF  interaction than  the sequence of contiguous amino acids. 
Although this AR region just NHn-terminal to the DNA- 
binding domain is required for RAF activity, no specific 
function has been attributed to  this region in  either AR or 
The observations that  RAF- AR and  RAF. GR complexes 
are disrupted by  AR52 and BuGR-2 antibodies, respectively, 
provide further evidence that RAF interacts directly with 
these receptors and  that regions in  the NHP-terminal  domains 
of  AR and GR  are  important for RAF interaction. The RAF 
interaction  site for rat AR (within  amino acids 460-520) is 
adjacent to  the epitope of the AR52 antibody (amino acids 
527-541).  Likewise, the epitope for the BuGR-2 antibody (rat 
GR amino acids 415-431) is in a region of the GR NHz- 
terminal domain comparable to that of the AR52 epitope. The 
proximity of the RAF interaction  site and  the antibody epi- 
topes could explain how these  antibodies block RAF activity, 
either by steric interference or by changes  in local conforma- 
tion of the receptor. Furthermore, the colocalization of the 
RAF interaction site and antibody epitopes implicates this 
NHp-terminal region in mediating stabilization of receptor- 
DNA binding since both RAF and antibody interactions  en- 
hance receptor-DNA binding. 
Although RAF enhances DNA binding of full-length human 
GR, we have been as yet unable to demonstrate a similar 
effect with full-length baculovirus-expressed rat or human 
AR. Experiments are in progress to determine if a specific 
condition or receptor conformation is necessary for RAF 
activity with full-length AR. Furthermore, we have not ruled 
out  the possibility that RAF can  interact only with receptors 
expressed in non-mammalian cells, since in our studies we 
utilized receptors overexpressed in E. coli and Sf9 insect cells. 
Also, since partially purified rabbit reticulocyte lysate was 
used in  this study, we cannot be certain that  the RAF inter- 
GR (53-55). 
acting with AR or GR  fragments  and  full-length GR is iden- 
tical. However, more extensive purification efforts indicate 
that these RAF activities are  attributable to  the same p r ~ t e i n . ~  
The formation of heteromeric complexes by protein-protein 
interactions is characteristic of many transcriptional activa- 
tors and may be important in generating diversity in the 
regulation of transcription (56). Examples include the  heter- 
odimerization of the leucine zipper class of proteins,  such  as 
fos/jun and ATF/CREB (57) and  the helix-loop-helix family 
of proteins, such as MyoD and E12/E47-like proteins (58). 
Although the specific biological function of RAF is unknown, 
the interaction of RAF with AR and  GR suggests that RAF 
might influence the ability of these receptors to activate 
transcription. The cloning of RAF will be an important  step 
toward understanding its biological significance. 
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